Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma
The phase II DISCUS trial investigated the effectiveness of 3 versus 6 cycles of platinum-based chemotherapy followed by avelumab maintenance in advanced urothelial cancer patients
New Reference: Panitumumab for Ras/Raf WT Metastatic Colorectal Cancer After Anti-EGFR Therapy
The study evaluated sequencing of panitumumab and regorafenib in chemorefractory colorectal cancer, showing no difference in overall survival but superior response rates and diseas
New Drug: Ziftomenib for Relapsed/Refractory NPM1-Mutated AML
Ziftomenib monotherapy led to a complete remission rate of 22% with a median overall survival of 6.6 months among relapsed/refractory NPM1-mutated AML patients. It was well tolerat
New Drug: Izalontamab Brengitecan for Metastatic Nasopharyngeal Carcinoma
Izalontamab brengitecan significantly improved objective response rate and progression-free survival compared to chemotherapy in heavily pretreated nasopharyngeal carcinoma patient
New Protocol: Ivonescimab with Chemotherapy for Untreated Advanced Squamous NSCLC
The HARMONi-6 trial showed that ivonescimab combined with chemotherapy significantly improved progression-free survival compared to tislelizumab combined with chemotherapy. The tre
New Protocol: Inotuzumab Ozogamicin Then Blinatumomab for Older Adults with Ph-Negative ALL
Inotuzumab ozogamicin followed by blinatumomab without chemotherapy showed high remission and survival rates in older patients with Ph-negative B-cell ALL. The regimen achieved a C
New Protocol: Glofitamab Plus Polatuzumab Vedotin for Relapsed/Refractory Large B-Cell Lymphoma
Glofitamab plus Polatuzumab Vedotin demonstrated a high and durable response, with an overall response rate of 78.3% and a median progression-free survival of 12.3 months in heavil
New Indication: Sacituzumab Govitecan for Untreated Advanced Triple Negative Breast Cancer
The ASCENT-03 trial demonstrated that sacituzumab govitecan significantly improved progression-free survival compared to chemotherapy in patients with untreated, advanced triple-ne
New Reference: 9-Year Results for Adjuvant Nivolumab in Melanoma
Nivolumab showed a longer recurrence-free and distant metastasis-free survival compared to ipilimumab at 9 years in patients with resected stage III or IV melanoma. The overall sur
